News

The FIXFc compound is a recombinant protein in early-stage development for the treatment of hemophilia B. The Fc fusion with Factor IX is intended to prolong the effect

Xenazine is said to be the first and only FDA-approved treatment specifically developed for any Huntington’s disease (HD)-related symptom. Xenazine will be distributed throughout the US via a

Pralatrexate (PDX) is said to be a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase (DHFR), a folic acid (folate)-dependent enzyme involved in the building of nucleic

The randomized, single-blind, controlled, multi-center Phase I clinical trial of the Intercept red blood cell system is expected to enroll approximately 28 healthy subjects. Each subject will receive

Upon approval by the European Commission in early 2009, Valdoxan is expected to be marketed by Servier in European countries in the following months. Data from the company’s

The study is designed to test the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation and to determine the

R&D services will be provided by Chemical Diversity Research Institute, ChemDiv’s research subsidiary based in Moscow. The new agreement provides for research funding of clinical candidate compounds to

Mr Davis, who previously served as the company’s vice president of sales and marketing from May 2007 to February 2008, has more than 20 years experience in the

This marketing approval authorization (MAA) submission will follow the centralized approval procedure with the British Medicines and Healthcare products Regulatory Agency acting as rapporteur and the Italian Agenzia